Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

Summary

The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period. The trial presents a detailed scientific justification for comparing UDCA to corticosteroids, describing the treatment and detailing the follow-up procedures. It hypothesizes that UDCA could be superior to corticosteroids for treating ICI-related cholestatic hepatitis, based on its established use in primary biliary cholangitis and a favorable tolerance profile compared to corticosteroids.

Eligibility

Inclusion Criteria:

* Adults ≥18 years old
* Any type of cancer except hepatocellular or cholangiocarcinoma
* At least one ICI injection
* Cholestatic hepatitis Grade CTC-AE 3 or 4

Exclusion Criteria:

* Ongoing corticosteroids treatment
* Other causes of hepatitis
* Cirrhosis
* ICI for hepatocellular carcinoma or cholangiocarcinoma
* Biliary obstruction
* Medical contraindication to corticosteroids or UDCA
* Mixed or hepatocellular hepatitis
* Total bilirubin \> 1,5 ULN, Prothrombin rate \< 70%
* Medical contraindication to MRI or liver biopsy
* Oher serious side effects requiring corticosteroids
* Pregnant and breast-feeding patients
* Patients under articles L1121-5 to 8 of the public health code
* Lack of informed consent
* Patients not affiliated with French social security system
* Patients uncapable of understanding french

Conditions2

Interventions2

Related trials

• FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy — Xijing Hospital of Digestive Diseases
• Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly — Phenomen Pharma
• Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors — Jinling Hospital, China

Browse More Trials